Klotho Neurosciences (NASDAQ:KLTO) Issues Quarterly Earnings Results

Klotho Neurosciences (NASDAQ:KLTO) posted its quarterly earnings results on Thursday. The company reported ($0.05) EPS for the quarter, Zacks reports.

Klotho Neurosciences Stock Down 2.0%

KLTO traded down $0.01 during midday trading on Friday, hitting $0.47. The stock had a trading volume of 309,401 shares, compared to its average volume of 714,815. Klotho Neurosciences has a 1 year low of $0.11 and a 1 year high of $3.91. The business has a fifty day moving average of $0.54 and a 200 day moving average of $0.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Klotho Neurosciences in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC acquired a new stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences at the end of the most recent quarter. 20.07% of the stock is currently owned by hedge funds and other institutional investors.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.